

**Government of Pakistan
Ministry of National Health Services, Regulations and Coordination
(Drug Regulatory Authority of Pakistan)

NOTIFICATION


Islamabad, the 19th May, 2023.

S.R.O. 595(I)/2023. – In exercise of the powers conferred by clause (a) of section 7 of the Drug Regulatory Authority of Pakistan Act, 2012 (XXI of 2012) read with section 12 of the Drugs Act, 1976 (XXXI of 1976) and sub-paragraph (8) of paragraph 12 of the Drug Pricing Policy-2018, the Drug Regulatory Authority of Pakistan with the approval of the Federal Government is pleased to fix maximum retail prices of drugs and biologicals, subject to the conditions specified below, namely:-

As a one-time dispensation, enabling manufacturers and importers to increase their existing MRPs of essential drugs and biologicals (excluding lower priced) equal to 70% increase in CPI (with a cap of 14%) and MRPs of all other drugs and biologicals and lower priced drugs up to increase in CPI (with a cap of 20%) on the basis of average CPI for current year i.e. the 01st day of July, 2022 to the 01st day of April 2023 subject to the following conditions, namely:-

- a) it shall be considered as annual increase under the said Policy for financial year 2023-24 and no increase under this category shall be granted in next financial year;
- b) the Policy Board of the Drug Regulatory Authority of Pakistan shall review the situation after three months i.e. in July 2023 and shall make its recommendations to the Federal Government for its consideration regarding price decrease, if Pak Rupee appreciates in value;
- c) hardship cases that have been recommended by the Drug Pricing Committee and are under submission for approval from the Federal Government, shall be reviewed for adjustment; and
- d) the revised maximum retail prices shall be printed on the label in the manner prescribed by the Drugs (Labeling and Packing) Rules, 1986 and manufacturers and importers of drugs and biologicals shall, before affecting increase, furnish calculations of revised maximum retail prices of drugs and biologicals to the Division of Costing and Pricing of the Drug Regulatory Authority of Pakistan.

[No.F.14-11/2023-AD (C&P)]


AAMAR LATIF,
Deputy Director (Legal Affairs).

The Manager,
Printing Corporation of Pakistan Press,
Islamabad.